Multicenter, randomized, investigator-masked study comparing brimonidine tartrate 0.1% and timolol maleate 0.5% as adjunctive therapies to prostaglandin analogs in normal tension glaucoma

Multicenter, randomized, investigator-masked study comparing brimonidine tartrate 0.1% and timolol maleate 0.5% as adjunctive therapies to prostaglandin analogs in normal tension glaucoma - Assessment of AIPHAGAN Addition in PG treated NTG (AAA-study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014810

Enrollment

144

Registered

2014-08-10

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal Tension Glaucoma

Interventions

0.1%Brimonidine Tartrate, b.i.d. for 12weeks 0.5%Timolol Maleate, b.i.d. for 12weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients have been treated with PGAs for at least 90 days 2) Patients with intraocular pressure of 16.0mmHg or lower

Exclusion criteria

Exclusion criteria: 1) Any active ocular disease 2) Highly visual field loss(e.g. the mean deviation<-20dB) 3) Corneal thickness is less than 450um, or more than 600um 4) History of trabeclotomy or trabeculectomy 5) Medical history of allergic or severe adverse event to brimonidine or timolol.

Design outcomes

Primary

Measure	Time frame
Mean changes from baseline intraocular pressure at week 12	—

Countries

Japan

Contacts

Public ContactShiro Mizoue

Ehime University Graduate School of Medicine Department of Ophthalmology

mizoue@m.ehime-u.ac.jp089-960-5361

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026